Sudeep Pharma FY26: Growth Accelerates, Mix Shifts, and New Capacity Comes Into Focus

Sudeep Pharma Limited closed FY26 with its highest reported revenue so far, supported by a stronger speciality ingredients mix and incremental contribution from its European acquisition, Nutrition Supplies Services (NSS). Consolidated revenue from operations rose to INR 642.3 crores in FY26, up 28% from INR 502.0 crores in FY25. Profitability also moved higher in absolute terms, with EBITDA at INR 221.9 crores (up 17%) and PAT at INR 174.3 crores (up 26%).

The year, however, was not a clean glide path. The company faced temporary disruptions in Q4 from gas supply issues, sharp increases in sulphuric and phosphoric acid prices, and supply chain disruption linked to the West Asia conflict. Even so, management emphasised that demand remained healthy across business verticals, and pricing revisions were implemented with customers, with benefits expected to show progressively over coming quarters.

FY26 performance: strong growth, softer margins

Q4FY26 revenue from operations came in at INR 182.3 crores, growing 16% year on year from INR 157.5 crores. EBITDA for the quarter was INR 62.6 crores versus INR 58.8 crores, while PAT rose to INR 48.5 crores from INR 44.2 crores.

The bigger picture is FY26’s step up in scale. But margin pressure was visible. EBITDA margin moderated to 34.6% in FY26 from 37.8% in FY25. PAT margin stayed relatively stable at 27.1% versus 27.6%.

Management attributed the margin compression to a combination of factors: higher operating costs from building out teams in Europe and North America, increased warehousing and inventory infrastructure, and the impact of running certain higher value product categories on smaller temporary capacity until the greenfield expansion is fully operationalised.

Mix shift continues: speciality ingredients rises to 44%

A key structural trend in Sudeep Pharma’s reported numbers is the steady rise of speciality ingredients. The revenue mix for FY26 was 56% pharma and food nutrition and 44% speciality ingredients, compared with 66% and 34% respectively in FY25.

Management also shared in the earnings call that speciality ingredients revenue rose from about INR 172 crores in FY25 to INR 280 crores in FY26. The company described this vertical as its fastest growing segment, benefiting from global traction in infant nutrition, medical nutrition, sports nutrition, and dietary supplements.

Beyond growth, the company is also signalling a move toward higher realisation molecules in its pharma, food and nutrition business. Management highlighted next generation mineral molecules such as bisglycinate, launched under the AbsorBis portfolio, citing enhanced absorption and higher value applications. During the call, management said the bisglycinate category is clinically positioned and could progressively contribute to growth and margin expansion as customer approvals translate into scale.

Working capital: FY26 deterioration and FY27 normalization target

The most visible balance sheet development in FY26 was the increase in net working capital days to 213 days from 184 days in FY25. Management linked this increase largely to higher inventory days.

The CFO quantified that inventory value increased by about INR 88 crores year on year. This included an increase of INR 41 crores in raw materials and INR 37 crores in finished goods. The finished goods build was described as strategic, aimed at supporting customer commitments in Europe and the US for upcoming quarters. On raw materials, the company increased inventory due to contract renewals and volatility in key inputs such as phosphoric acid.

Management also pointed to operational factors: newly established warehousing operations in the US and Europe, consolidation of NSS inventory where the sales contribution was for nearly 10 months, and longer lead times due to geopolitical disruptions.

Importantly, the company set a clear internal target. The CFO stated that management is targeting net working capital days to come down to around 150 to 160 days within FY27 through tighter inventory management, improved receivable collections, and broader working capital optimization.

Capital allocation: greenfield completion and a new battery materials platform

FY26 was also a year of heavy investment. Consolidated investing cash flow was negative INR 330.9 crores, versus INR 78.8 crores in FY25, reflecting capex and acquisition related outflows.

The investor presentation details two major capacity initiatives.

First is the Nandesari greenfield project. The company disclosed a total capex of about INR 150 crores and annual capacity of 51,200 MT, focused on pharmaceutical excipients, actives, and food and nutrition minerals. Management stated internal validation is completed and customer validation is underway. The next stage is customer qualification trials, which management expects to take about 6 to 12 months depending on customer audits and product categories.

Second is the battery materials project at Dahej under Sudeep Advanced Materials, focused on battery grade iron phosphate for LFP batteries. The presentation cites a project cost of approximately INR 300 crores, to be financed through internal accruals and debt, with completion targeted by early CY2027. On the call, management said Phase 1 capacity of 25,000 MT per year remains on track for commissioning by April 2027.

Customer engagement metrics were also disclosed for the battery materials vertical. Management stated the company is engaged with 42 customers across Korea, Japan, Indonesia, India, Europe, and the US. It also shared a funnel view: 22 customers at lab validation, 14 at pilot scale evaluation, and six customers having completed commercial validation with active off take discussions. The company also stated it has started receiving initial commercial purchase orders, including about 700 MT over the last month alone.

Outlook: what to watch from here

While the company did not provide explicit revenue guidance, the call offered directional visibility. Management expects pharma and food nutrition growth to improve from the 10% recorded in FY26, aided by new customer approvals and the commissioning of the greenfield facility. It also expects speciality ingredients to remain the faster growing segment, supported by new approvals and investments in North America and Europe.

On margins, management stated it expects consolidated margins to trend back toward historical levels seen in FY24 and FY25 as investments in teams and warehousing begin to contribute positively. The company also stressed that pricing actions taken to offset raw material inflation should reflect progressively in coming quarters.

From a balance sheet lens, leverage remains modest. The CFO stated net debt was INR 33.6 crores as of 31 March 2026, with net debt to equity at 0.04x.

The FY26 narrative is therefore a blend of near term execution challenges and long term platform building. The next few quarters are likely to be evaluated on three visible markers: the pace of working capital normalization, the progress of greenfield customer qualifications, and whether speciality ingredient momentum sustains while the company prepares for commissioning of its battery materials capacity.